RANK 16
Revenue 84.17 Crore
|
Advanced
Microdevices |
MD: Mr Nalini Kant Gupta
|
Business: Production
of microporous membranes and separation products
|
Start-up Year: 1976
|
Address: No.20-21, Industrial Area,
Ambala Cantonment, Haryana-33006
Tel: +91-171-2699290/471
Fax: +91-171-2699221/008
Website: www.mdimembrane.com |
A new 85,000 sq ft state-of-the-art
GMP facility has been set up recently by the company at a cost of over
20 crore
![](http://biospectrumindia.ciol.com/images/content/2011/jul/17-Nalini-Kant-Gupta-%28MD-Ad.jpg)
Advanced Microdevices (MDI) registered a
growth of over 21 percent in 2010-11 with an estimated revenue of
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
68
crore in 2010-11 as compared to
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
56 crore in 2009-10.
A new 85,000 sq ft state-of-the-art GMP facility has been set up
recently by the company at a cost of over
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
20 crore. This facility
includes a 10,000 sq ft Class 10,000 (ISO 7) clean production area. It
also houses a 9,000 sq ft well equipped filter validation lab with all
the necessary instruments that are required to deal with modern day
drug formulations, novel drug delivery systems (NDDS), oncology drugs
and therapeutic recombinant proteins.
Products are exported to more than 50 countries worldwide, including
US, Western Europe, China and South Korea. The company has deep
penetration in the India biopharmaceutical industry and enjoys dominant
position in many product segments. An overseas office has recently been
set up in California, US and work is on for setting up a new joint
venture company in the US.
Advanced Microdevices included nucleic acid isolation, purification,
and separation kits in its product range. The company also produces
very consistent nitrocellulose membranes for rapid immunodiagnostic
tests, whose quality is world renowned. MDI is the global leader in
these membranes. The MDI red blood cells (RBC) separator for lateral
flow tests is the best in the market in terms of efficacy and
efficiency. A unique rapid plasma separation device has been developed
for use with quantitative diagnostic analyzers and point of care
applications (patent pending). The focus at MDI is on using its
membrane technologies as a platform for developing new value added
products for use in filtration and separation.
MDI product portfolio boasts of more 15,000 products, manufactured in
an ISO 9001:2008 certified production facility and are CE certified. A
Drug Master File for the filtration products was submitted to the USFDA
in the year 2002.